title: Activation of the AKT/cyclin D1/Cdk4 survival signaling pathway in radioresistant cancer stem cells.
abstract: Radioresistance, which is a major cause of failure of radiotherapy (RT), is proposed as one of the intrinsic characteristics of cancer stem cells (CSCs) whose unique DNA damage response (DDR), efficient DNA repair and resistance to apoptosis are thought to confer the phenotype. We have isolated surviving CSCs by exposure to long-term fractionated radiation for 82 days from HepG2 and A172 cells (82FR-31NR cells). 82FR-31NR cells exhibited CSC properties, such as high expression of CSC marker CD133 and the ABC transporters (MDR1 and BCRP1), and high tumorigenic potential after transplantation into nude mice. The advantage of our isolated CSCs is that they can proliferate in as the same growth medium as that of parental cells without loss of CSC properties. Therefore, we can analyze DDR of non-stem cells and CSCs without any influences caused by different culture conditions. 82FR-31NR cells showed efficient DNA repair of radiation-induced DNA damage and radioresistance with activation of the AKT/cyclin D1 survival signaling pathway. In contrast, DNA damage persisted for a long time after irradiation in parental cells compared with isolated CSCs. Persisted DNA damage induced apoptosis in parental cells without activation of the AKT/cyclin D1 pathway. Therefore, inhibition of the AKT/cyclin D1 pathway by an AKT inhibitor, API-2, or cyclin D1 siRNA resulted in a loss of efficient DNA repair and radiosensitization of 82FR-31NR cells. Furthermore, knockdown of Cdk4 by its siRNA or a Cdk4 inhibitor was sufficient to suppress radioresistance of CSCs. In this study, we present a newly discovered DDR regarding the AKT/cyclin D1/Cdk4 pathway in response to radiation in CSCs. Combination of fractionated RT and reagents targeting the AKT/cyclin D1/Cdk4 pathway to eradicate CSCs would be effective therapeutic modality.
authors.affiliation: Department of Pathology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Shimura
authors.forename: N
authors.initials: N
authors.lastname: Noma
authors.forename: T
authors.initials: T
authors.lastname: Oikawa
authors.forename: Y
authors.initials: Y
authors.lastname: Ochiai
authors.forename: S
authors.initials: S
authors.lastname: Kakuda
authors.forename: Y
authors.initials: Y
authors.lastname: Kuwahara
authors.forename: Y
authors.initials: Y
authors.lastname: Takai
authors.forename: A
authors.initials: A
authors.lastname: Takahashi
authors.forename: M
authors.initials: M
authors.lastname: Fukumoto
references.citation: Nature. 2006 Dec 7;444(7120):756-60
references.pmid: 17051156
references.citation: Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):540-8
references.pmid: 21398050
references.citation: PLoS Biol. 2009 Jun 2;7(6):e1000121
references.pmid: 19492080
references.citation: Curr Stem Cell Res Ther. 2009 May;4(2):147-53
references.pmid: 19442199
references.citation: Genes Dev. 2008 Feb 15;22(4):436-48
references.pmid: 18281460
references.citation: Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):268-73
references.pmid: 19116269
references.citation: Nature. 2011 Jun 08;474(7350):230-4
references.pmid: 21654808
references.citation: Dis Esophagus. 2011 May;24(4):265-73
references.pmid: 21087344
references.citation: Cell Stem Cell. 2007 Sep 13;1(3):313-23
references.pmid: 18371365
references.citation: Cancers (Basel). 2011 Mar;3(1):1232-52
references.pmid: 21603589
references.citation: Blood. 2003 Aug 1;102(3):972-80
references.pmid: 12702506
references.citation: J Mol Biol. 2008 Jan 25;375(4):1152-64
references.pmid: 18054789
references.citation: Science. 2001 Jul 13;293(5528):293-7
references.pmid: 11452123
references.citation: J Natl Cancer Inst. 2006 Dec 20;98(24):1777-85
references.pmid: 17179479
references.citation: Oncogene. 2006 Sep 28;25(44):5921-32
references.pmid: 16682953
references.citation: Nat Rev Cancer. 2002 Jul;2(7):489-501
references.pmid: 12094235
references.citation: J Biol Chem. 2003 Oct 3;278(40):39068-75
references.pmid: 12851395
references.citation: Drug Metab Dispos. 2005 Jul;33(7):905-9
references.pmid: 15843490
references.citation: Acta Biochim Biophys Sin (Shanghai). 2010 Sep;42(9):593-602
references.pmid: 20705681
references.citation: J Biol Chem. 2007 Jul 20;282(29):21206-12
references.pmid: 17513297
references.citation: Cancer Biol Ther. 2003 May-Jun;2(3):233-5
references.pmid: 12878854
references.citation: Mol Cancer. 2007 Apr 02;6:24
references.pmid: 17407548
references.citation: Blood. 2002 Jun 15;99(12):4554-61
references.pmid: 12036888
references.citation: Stem Cells Dev. 2009 Oct;18(8):1127-34
references.pmid: 19409053
references.citation: Radiother Oncol. 2011 Jun;99(3):300-6
references.pmid: 21704411
references.citation: Nat Rev Cancer. 2008 Jul;8(7):545-54
references.pmid: 18511937
references.citation: Cell. 2007 Jun 29;129(7):1261-74
references.pmid: 17604717
references.citation: Radiat Oncol Investig. 1999;7(6):321-30
references.pmid: 10644055
references.citation: Nat Rev Cancer. 2003 Dec;3(12):895-902
references.pmid: 14737120
references.citation: Nat Rev Cancer. 2005 Jul;5(7):516-25
references.pmid: 15965493
references.citation: Radiat Res. 2003 Mar;159(3):283-300
references.pmid: 12600231
references.citation: Stem Cells. 2008 Dec;26(12):3027-36
references.pmid: 18802038
references.citation: Oncogene. 2008 Mar 13;27(12):1749-58
references.pmid: 17891174
references.citation: Nat Rev Cancer. 2011 Jul 07;11(8):558-72
references.pmid: 21734724
references.citation: Blood. 2006 Sep 1;108(5):1744-50
references.pmid: 16690963
references.citation: Oncogene. 2010 Aug 26;29(34):4826-37
references.pmid: 20562919
references.citation: Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):91-8
references.pmid: 8083133
references.citation: Cell Stem Cell. 2009 Mar 6;4(3):226-35
references.pmid: 19265662
references.citation: Biochem Cell Biol. 2003 Jun;81(3):123-9
references.pmid: 12897845